XML 36 R19.htm IDEA: XBRL DOCUMENT v3.25.0.1
Goodwill and Other Intangible Assets, Net
 12 Months Ended
Dec. 31, 2024
Goodwill and Intangible Assets Disclosure [Abstract]  
Goodwill and Other Intangible Assets, Net Goodwill and Other Intangible Assets, Net
Goodwill
The change in the carrying amount of goodwill for the period is as follows:
Years Ended December 31,
(in millions)
2024
2023
Goodwill at beginning of the year
$51.7 $51.7 
Foreign currency translation(0.2)— 
Goodwill at end of the year$51.5 $51.7 
Intangible Assets, Net
The gross carrying amount, accumulated amortization and net book value of intangible assets at the end of each period were as follows:
 As of December 31,
20242023
(in millions)Gross Carrying AmountAccumulated AmortizationNet Book ValueGross Carrying AmountAccumulated AmortizationNet Book Value
Customer relationships$43.1 $(33.5)$9.6 $43.2 $(30.9)$12.3 
Internal-use software52.4 (15.6)36.8 43.1 (13.9)29.2 
Developed technology
27.4 (4.9)22.5 27.4 (3.0)24.4 
Patents
36.2 (6.6)29.6 36.2 (3.4)32.8 
Total intangible assets $159.1 $(60.6)$98.5 $149.9 $(51.2)$98.7 
Amortization expense for intangible assets was $9.8 million, $10.2 million, and $7.2 million for the years ended December 31, 2024, 2023, and 2022, respectively.
In February 2023, the Company paid Bigfoot Biomedical, Inc. $25.1 million, including transaction costs, to acquire patent assets related to pump-based automated insulin delivery technologies. The acquired patent assets have a useful life of 11 years.
Amortization expense associated with the intangible assets included on the Company’s consolidated balance sheet as of December 31, 2024 is expected to be as follows:
Years Ending December 31, (in millions)
2025$14.2 
2026$15.1 
2027$14.0 
2028$12.9 
2029$12.3